Akèy › Limfòm folikilè › North Carolina
Etid klinik pou Limfòm folikilè nan North Carolina
23 etid pou Limfòm folikilè ap chèche patisipan nan sit nan North Carolina.
Vil nan North Carolina
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Charlotte
- Research Site, Winston-Salem
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06542250A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- Duke Cancer Center Clinic 1B/C Onc/Heme ( Site 1307), Durham
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07634471A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Research Site, Charlotte
- Research Site, Wilmington
- Research Site, Winston-Salem
Ap rekriteFaz 3
Laj 18 a 130 · Tout sèks · Mizajou Sep 21, 2026 · NCT06549595Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Charlotte
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06526793A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- University of North Carolina, Chapel Hill
- Levine Cancer Institute, Charlotte
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06091254A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- Novant Health Weisiger Cancer Institute, Charlotte
Ap rekriteEtid obsèvasyon
Laj 0 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07154823Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Wake Forest University Health Sciences, Winston-Salem
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06860594SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Duke Cancer Institute, Durham
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT05303519A Study of ARC-02 in B-cell NHL
- Levine Cancer Institute, Charlotte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07691606Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Atrium Health Wake Forest Baptist, Winston-Salem
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579Pain With Dementia
- Duke University Medical Center, Durham
Ap rekriteVolontè an sante akeyi
Laj 50 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06854718A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Duke University Medical Center, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT05131022Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
- North Carolina Basnight Cancer Hospital, Chapel Hill
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 1, 2026 · NCT06860880Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- ak 4 plis
Ap rekriteEtid obsèvasyon
Laj 65 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT01137825Study of SGR-1505 in Mature B-Cell Neoplasms
- Duke University, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT05544019Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- Duke Univerisity, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT04775745Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT04223765AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Duke University, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Dec 10, 2025 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Oct 27, 2025 · NCT01137643A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University of North Carolina, Chapel Hill
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2025 · NCT05780034Cognition, Flavonoids, Exercise, Gut Microbiome
- Appalachian State University Human Performance Lab, North Carolina Research Campus, Kannapolis
Ap rekriteVolontè an sante akeyi
Laj 65 a 85 · Tout sèks · Mizajou Mar 12, 2025 · NCT06495190Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.